Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GeneQuantum OK'd to Start US Trials of Novel HER2 ADC

publication date: Jun 11, 2020

GeneQuantum Healthcare of Suzhou received IND approval in the US for its proprietary next-gen antibody drug conjugate asset, GQ1001. GQ1001 is a novel ADC drug candidate that is aimed at HER2-positive tumors. The candidate was developed using GQ's novel intelligent Ligase-Dependent Conjugation (iLDC) platform including a unique linker. GQ believes the platform will manufacture high quality ADCs in any mAb facility at a speed and yield similar to equivalent mAbs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital